Last updated: August 4, 2025
Introduction
Patent CN113620933, filed with a priority date in 2021, represents an innovative contribution to the Chinese pharmaceutical patent landscape. This patent appears to focus on novel drug compositions, formulations, or methods—potentially addressing therapeutic needs or advancing pharmaceutical efficacy. This analysis dissects its scope, claims, and position within the current patent landscape, providing insight for industry stakeholders, R&D entities, and patent strategists.
Scope of Patent CN113620933
Subject Matter Focus
While the complete textual details of CN113620933 require in-depth legal review, available summaries and abstracts suggest that the patent covers specific chemical entities, pharmaceutical formulations, or delivery methods. The scope likely encompasses:
- Novel compound compositions: Potentially small molecules, biologics, or drug conjugates with enhanced efficacy or reduced side effects.
- Delivery systems: Innovative formulations facilitating targeted delivery, controlled release, or improved stability.
- Manufacturing methods: Specific processes for preparing the compounds or formulations, emphasizing efficiency, purity, or scalability.
Scope Limitations
The patent’s scope is confined to the claims granted, which define the legal boundaries. Strategic claim drafting probably emphasizes:
- Structural features of compounds or formulations.
- Use-specific claims for treating particular diseases or conditions.
- Claims covering combinations with other agents, enabling broad protection.
Claims Analysis
Claims Structure
Patent claims are the crux of patent protection, with independent claims establishing broad coverage, and dependent claims narrowing or specifying particular embodiments.
1. Independent Claims
Likely include:
- Chemical Structure Claims: Covering specific molecular formulas or subclasses with particular functional groups. The claims possibly specify a core scaffold with substituents, emphasizing structural novelty.
- Use Claims: Claiming the therapeutic application of these compounds for particular diseases—e.g., cancers, neurodegenerative disorders, or infectious diseases.
- Formulation Claims: Protecting unique pharmaceutical forms—e.g., sustained-release matrices, nanoparticle encapsulations, or targeted delivery systems.
- Process Claims: Covering methods of synthesis or formulation preparation that confer advantages over existing technology.
2. Dependent Claims
Refine independent claims by listing:
- Specific substitutions on the core structure.
- Particular dosage forms or delivery protocols.
- Stabilizing agents or excipients used within the formulation.
- Specific combinations with other active pharmaceutical ingredients (APIs).
Claim Strategies
The patent likely employs broad broad claims to secure maximal coverage, with narrower dependent claims for fallback positions. This approach grants defensibility against challenges and licensing leverage.
Patent Landscape and Competitive Position
1. Technological Field Context
CN113620933 resides within a vibrant segment of China's pharmaceutical innovation—intensely competitive with both domestic and multinational entities. China's patent filings in pharmaceuticals have surged, with emphasis on:
- Novel therapeutics based on minor structural modifications.
- Drug delivery innovations to overcome bioavailability challenges.
- Combination therapies for complex diseases.
2. Prior Art and Patent Interactions
The patent landscape includes multiple related filings:
- Patents on similar chemical scaffolds or therapeutic indications.
- Patent families targeting the same disease pathways.
- Existing patents on delivery formulations with overlapping features.
CN113620933’s claims are likely crafted to navigate around prior art, emphasizing unique structural features or specific use applications.
3. Patent Family and Geographic Coverage
Given China's robust patent system, the patent may be part of a broader family covering filings in key jurisdictions like the U.S., Europe, and Asia-Pacific. This strategy enhances global protection and potentially blocks generic entry.
4. Patent Validity and Freedom-to-Operate
The patent’s validity depends on examining prior art references, especially existing chemical compounds and formulations. It is crucial to assess whether the claims are sufficiently novel and inventive to withstand future invalidation procedures.
Implications for Industry and R&D
- Licensing Opportunities: The patent’s claims on novel compounds may open licensing or partnership prospects.
- Competitive Advantage: If the claims cover a breakthrough formulation or delivery method, it positions the patent holder favorably for market entry.
- Patent Litigation: Broad independent claims risk infringement disputes; detailed claim scope analysis is vital for enforcement or defense strategies.
Conclusion
Patent CN113620933 demonstrates strategic claim drafting to secure broad protection in the Chinese pharmaceutical patent landscape. Its scope likely encompasses innovative structures, formulations, and uses addressing contemporary therapeutic challenges. For stakeholders, understanding its claim boundaries and positioning within China's patent ecosystem is essential for optimizing licensing, R&D investments, and competitive strategies.
Key Takeaways
- The patent’s scope emphasizes structural novelty, therapeutic use, and formulation technologies, with layers of claims supporting broad and fallback protections.
- The patent landscape is highly dynamic, with prior art necessitating precise claim drafting; ongoing monitoring of related filings is critical.
- CN113620933's protection may impact licensing, collaborations, and potential patent litigations in China.
- Strategic positioning requires thorough infringement and validity assessments aligned with evolving patent landscape trends.
- Industry actors should consider this patent within their R&D roadmap and intellectual property portfolio management.
FAQs
1. What is the primary innovation claimed by CN113620933?
The patent primarily claims novel chemical compounds, therapeutic uses, and potentially innovative delivery formulations, designed to improve efficacy and reduce side effects for specific diseases.
2. How does CN113620933 compare to existing patents in the same therapeutic area?
It likely features structural or application-specific modifications that distinguish it from prior art, emphasizing unique substitutions or delivery methods to establish patentability.
3. Can this patent be enforced against generic manufacturers?
Yes, if the claims are upheld as valid, they can be used to assert infringement against generic entrants producing similar compositions or delivery systems within China.
4. What strategic considerations should companies keep in mind concerning this patent?
Entities should evaluate its claim scope, monitor related filings, and consider licensing opportunities or infringement risks, especially when developing similar therapeutics in China.
5. Does this patent have international equivalents?
While primarily granted in China, similar patent families may exist elsewhere—strategic patent filings in key jurisdictions can bolster global protection.
References
[1] Chinese Patent Office. Official patent document for CN113620933.
[2] WIPO PatentScope. Analysis of Chinese pharmaceutical patents.
[3] Chinese Patent Gazette. Patent landscape reports in biotechnology.
